Page 13 of 22 FirstFirst ... 345678910111213141516171819202122 LastLast
Results 121 to 130 of 212

Thread: The 4-AP List

  1. #121
    Senior Member NW-Will's Avatar
    Join Date
    Apr 2008
    Location
    Vancouver WA USA - - Male T4 ASIA B incomplete
    Posts
    1,821
    Quote Originally Posted by Pluto64 View Post
    Ok, I’m ready to try 4-AP. Getting together info for my doctor. Next questions is if I’m given a prescription, what compounding pharmacy has the experience to fill it for me?

    Any compounding pharmacy’s located in IL?

    Next question, just to be a little lazy, can some one post a link of the information of what you gave to your doctor with information on what dose to start out with.
    I just asked my pharmacy where the closest compounding pharmacy was. They were already filling 4-ap prescriptions for lots of MS patients.

    This is what I took to the Doctor.

    http://sci.rutgers.edu/forum/showpos...7&postcount=83

  2. #122
    Senior Member NW-Will's Avatar
    Join Date
    Apr 2008
    Location
    Vancouver WA USA - - Male T4 ASIA B incomplete
    Posts
    1,821
    Quote Originally Posted by keeping on View Post
    Guys and Gals, we're talking about 4ap and dosages. What benefits are any of you seeing? This is important ;as I understand it; the elctrical circuit is supposed to be increased in efficency, and for one I am interested in trying it. About 8 months ago, I approcahed it with my neuro and he said it was somewhat dangerous, but would revisit it with me this next vist. Hey any improvement woudl be welcome.

    T.J.
    Nothing to report here.
    I'm only on my second month though.
    Now up to 40mg a day with no side effects.

  3. #123
    Come on guys, NWWill isn't the only one trying 4ap; what results are you seeing with the use of this compound? It's important to either verify psoitive results or no results for the rest of us. I'd like to have first hand info when I see my neuro in April.

  4. #124
    Quote Originally Posted by keeping on View Post
    Come on guys, NWWill isn't the only one trying 4ap; what results are you seeing with the use of this compound? It's important to either verify psoitive results or no results for the rest of us. I'd like to have first hand info when I see my neuro in April.
    Keeping on,

    There are hundreds of posts going back more than 10 years from people who have used 4-AP. If you want, you should be able to do a search.

    Wise.

  5. #125
    Senior Member NW-Will's Avatar
    Join Date
    Apr 2008
    Location
    Vancouver WA USA - - Male T4 ASIA B incomplete
    Posts
    1,821
    Ok this is somewhat tongue in cheek, but seriously, I was wondering how much avitrol would cost !!!

    avitrol

    Only been able to find prices in Australia...
    No luck in finding the dosage comparison either.

    Damn those lucky pigeons with SCI.

    old news but still interesting...
    http://www.sci-therapies.info/Pharm-Chronic.htm#4AP

    4-Aminopyridine (4AP or Fampridine-SR): 4AP is a small molecule that restores some function in some individuals with SCI. Basically, it works by improving the conduction of intact but demyelinated neurons that often still transverse the SCI injury site in not only incomplete but clinically classified complete injuries. It has been estimated that a third of those with SCI can accrue some benefit from 4AP.

    Because demyelinated neurons have lost their insulating sheath, they no longer can transmit a signal. Without the insulating myelin, potassium channels (called fast voltage-sensitive potassium channels) are exposed on the axonal surface, letting potassium ions leak out of the axon, in turn, short-circuiting neuronal transmission. By blocking these channels, 4AP increases action potential duration, allowing signal conduction through the demyelinated sections and, as a result, increasing neurotransmitter release from the axon.

    Because its mechanism of action involves demyelinated neurons, 4AP was first tested in individuals with multiple sclerosis (MS). Both SCI and MS are disorders characterized by the loss of insulating myelin around neurons; in SCI, the loss is from injury, and with MS, it is from autoimmune-mediated causes.

    Because 4AP does not stimulate regeneration or improve any post-injury physiology or biology, it not a cure but a transient enhancer of existing function, i.e., a temporary fix.

    Once the body eliminates 4AP, benefits are lost. The sustained-release formulation of 4AP (Fampridine-SR) peaks in the blood about 2-3 hours after administration and has a half life of roughly 6-7 hours. In studies measuring the elimination of orally administered 4AP tagged with a radioactive tracer, virtually all of the drug had been eliminated 24 hours after administration. To maintain a benefit-sustaining plasma level, 4AP must be taken several times daily on an ongoing basis. In other words, any restored function will dissipate after stopping the drug.

    Surveys taken on SCI-focused websites suggest that 15% of those with SCI have taken 4AP, which is available through compounding pharmacies (i.e., pharmacies that make medicines from agents that doctors prescribe). The recommended daily dose of the immediate-release formulation made by the compounding pharmacies is 40 mg/day, administered in periodic 10-mg doses. In contrast, Acorda Therapeutics has developed a sustained-released formulation (Fampridine-SR) with a longer half life. With this formulation, a 40-mg dose can be given twice a day.

    Originally used as a bird repellent (trade name Avitrol), 4AP is not innocuous and can have significant side effects. Finding a dose that maximizes benefits while minimizing side effects has been challenging. In some, the most effective dose is close to one that causes side effects. Because 4AP stimulates the nervous system, side effects include insomnia, nervousness, tingling, increased blood pressure, heart rate, and seizures.

    In a case report, 4AP’s potential toxicity was documented in a 42-year-old man with a C3 injury, who had been taking 4AP prepared by a compounding pharmacy (ref). His 4AP pills contained 10-times the dose indicated on the label, a dose which routinely causes toxicity. As a result, he had to be taken to the hospital emergency room. According to the report, “He recovered with permanent short-term memory loss after a prolonged and complicated hospital course.”

    There seems to be some dichotomy between patients and scientists on 4AP’s risks relative to benefits. Specifically, many professional articles seem to minimize the risks while much of the anecdotal discussion posted on SCI websites suggests benefits are subtle relative to side effects.

    Acorda Therapeutics, a biotechnology company focused on spinal cord dysfunction, has been the leading force behind the development of 4AP as a function-restoring agent for SCI. In fact, many of the published papers have been authored by scientists who have close associations with Acorda.

    Unfortunately, after a decade of commitment, Acorda 4AP’s research-and-development efforts have fallen short for SCI, and the company is redirecting it efforts toward the substance’s MS benefits.

    Specifically, in 2004, the company completed two phase-3 clinical trials involving their sustained-release formula Fampridine-SR. Perhaps due to a number of confounding issues that lessened study robustness, trial results did not demonstrate sufficient statistical significance for the two endpoints measured, spasticity reduction (using the Ashworth score) and the Subject Global Impression rating. Acorda’s problems underscore the overall difficulty of selecting appropriate test endpoints for potential function-restoring interventions for chronic SCI.

    Considerable animal and human research has been carried out on 4AP over the last several decades. Some of the early animal research leading up to human trials were succinctly reviewed by Dr. Stephen Waxman (New Haven, Conn) (J Neurotrauma 10(1), 1993).

    The following summarizes in chronological order some key human studies:

    1) Hansebout et al. (Hamilton, Ontario) administered 4AP by infusion to eight subjects with chronic SCI using a randomized, crossover design, in which each patient received 4AP or placebo and then switches treatment. Improvements were noted in five of six subjects with incomplete SCI; none were observed in the two patients with complete injuries. Improvements included increased motor control and sensitivity, and reduction in pain and spasticity (J Neurotrauma 10(1), 1993).

    2) Hayes and colleagues (London, Ontario) assessed the effects of intravenous 4AP on electrophysiological conduction in six patients with SCI. Two patients had increases in amplitude of cortical somatosensory evoked potentials (SEPs), and four had increases in amplitude of motor- evoked potentials (MEPs). Clinical improvements included reduced spasticity (2) and pain (1), and increased sensation (1), leg movement (3), and bowel control (1) (J Neurotrauma 11(4), 1994).

    3) Segal et al (Long Beach, California) demonstrated that a single 10-mg dose of 4AP improved pulmonary function in patients with quadriplegia. Specifically improvements were noted in forced vital capacity, maximal inspiratory and expiratory pressure beginning six hours and lasting 12 hours after dosing (Pharmacotherapy 17(3), 1997).

    4) Potter et al. (London, Ontario) described improvements in three patients with incomplete quadriplegia who took 10-mg oral doses of 4AP twice or three times daily over four months. In addition to marked and sustained reduction in spasticity, other benefits included reduced pain (1), restored muscle strength (3), improved sensation (2), voluntary bowel control (1), erectile function (2), improved hand function (1), and enhanced transfers and gait (2). One patient stood with support for the first time since injury 16 years earlier (Spinal Cord 36(3), 1998).

    5) Potter et al (London, Ontario) reported the results of a randomized, double-blind, crossover study designed to assess the safety and efficacy of the Fampridine-SR sustained-release formulation. Twenty-six patients with incomplete SCI received either 4AP or placebo for two weeks followed by a one one-week washout period after which treatments were reversed. Improvements were reported with patient satisfaction, quality of life, sensation, motor function, and spasticity. No statistically significant benefits were documented for pain; bowel, bladder, or sexual function; or functional independence (J Neurotrauma 15(10), 1998).

    6) Segal et al (Long Beach, California) studied 4AP’s effects on ambulatory parameters in nine males (6 quadriplegic and 3 paraplegic) with some walking ability. Parameters included velocity (meters/min), cadence (steps/min), stride length (meters), gait cycle (seconds), and double-limb support (percent of gait cycle). After 4AP dosing, statistically significant changes were noted in various parameters (J Spinal Cord Med 21(3), 1998).

    7) In a randomized, dosage-blinded study, Segal et al (Long Beach, California) compared sensorimotor function in 16 subjects with SCI who had received 30-mg/day 4AP (high-dose) for three months with five subjects who received a 6-mg/day low dose. High-dose patients had decreased spasticity, and improved motor and sensory scores and pulmonary function (Pharmacotherapy 19(6), 1999).

    8) In a randomized, double-blind, crossover study, Van der Bruggen et al (Amsterdam, Netherlands) concluded that 4AP had no statistically significant effects on functional status, walking speed and vibration perception in 20 patients with incomplete SCI (J Neurol 8(8), 2001).

    9) Segal et al (Long Beach, California) compared the effects of a single 10-mg, 4AP dose on heart-rate variability - as a measure of the autonomic nervous system - in 13 subjects with SCI with 13 able-bodied controls. The difference in pre-test heart-rate variability between subjects with SCI and able-bodied controls disappeared in the 24 hours immediately after 4AP administration (Am J Ther 9(1) 2002).

    10) Grijalva and colleagues (Mexico City, Mexico) randomized 27 patients with SCI to receive an escalating 4AP dose or placebo for 12 weeks, after which treatments were reversed. Compared to placebo controls, improved motor function, sensation and independence were observed in 4AP-treated patients. The investigators noted persistent 4AP effects on sensation and independence 12 weeks after subjects were switched to placebo. Fifty-six percent of patients had adverse reactions (Pharmacotherapy 23(7), 2003).

    11) Hayes and colleagues (London, Ontario) studied pharmacokinetics in 16 patients with incomplete SCI (ASIA grade B-D) after dosing with 25-60 mg of Fampridine–SR twice daily for one week. Peak plasma concentration occurred 2.2-3.0 hours after dosing and drug half life was 5.7-6.9 hours. The investigators concluded that 1) adverse effects were mild or moderate and not dosage related and 2) this sustained release formulation was slowly absorbed and eliminated (Arch Phys Med Rehabil 85(1), 2004).

    12) Acorda Therapeutics sponsored a phase-2 clinical trial comparing subjects treated with high- or low-dose, sustained-released 4AP formulations (i.e., Fampridine SR) with placebo-treated subjects (Cardenas DD, et al, Spinal Cord 45, 2007). Each group contained ~30 subjects. Subjects had sustained incomplete injuries at least 18 months earlier (i.e., chronic injuries), ranged in age from 18 to 70 years, and had injuries between the cervical C4 and thoracic T10 levels. Eighty percent were men, and 92% were Caucasian.

    High and low-dose subjects received 40 and 25 milligrams of the drug, respectively, twice daily for four weeks. Forty-three percent of the high-dose subjects dropped out mostly due to a variety of adverse side effects. The low-dose regimen seemed to be better tolerated with an attrition rate of only 13% compared to 10% for placebo-treated subjects, respectively.

    Outcomes were evaluated by a variety of measurements, including, patient-diary questionnaires, quality-of-life assessments, erectile function, bladder and bowel management, spasticity, and clinician views of overall improvement. Although the study lacked the statistical robustness to draw firm conclusions for many of the outcome variables, some improvements seemed to accrue for quality of life, spasticity, and erectile function.

    13) Segal and colleagues (USA) evaluated 4AP’s effects on glucose tolerance in 31 individuals with injuries sustained at least a year earlier (ref). In general, individuals with SCI are prone to impaired glucose tolerance or diabetes. After fasting, subjects ingested 75 grams of glucose and completed a five-hour glucose-tolerance test, an assessment which basically measures how effectively the body can clear glucose from the blood. Before treatment, 29 of the 31 subjects had impaired glucose tolerance. In contrast, after six months of treatment with an oral, immediate-release 4AP formulation, only 12 had impaired glucose tolerance.

    14) Grijalva and associates (Mexico) evaluated the impact of 4AP on gastric emptying in patients with chronic injuries (ref). SCI can adversely affect the gastrointestinal tract, slowing the movement of solids though the stomach and colon. Signs of a neurogenic bowel include fecal impaction, constipation, abdominal distention, prolonged bowel care, and delayed colonic transit. It has been estimated that 41-86% of individuals with SCI have some of these problems, and 41% spend at least one hour daily on bowel care.

    In this specific study, 18 subjects with chronic SCI (9 with cervical injuries and 9 with thoracic injuries) were given daily oral doses of 4AP for 12 weeks. Gastric emptying was measured before and after this period. The results indicated that “4AP intake in patients with chronic spinal cord injury significantly slowed gastric emptying regardless of level and ASIA score of injury.”
    Last edited by NW-Will; 02-16-2010 at 10:19 PM. Reason: typo

  6. #126
    Senior Member
    Join Date
    Sep 2007
    Location
    Fithian, IL
    Posts
    1,967
    At first I thought, oh my he must be having a really bad that he wants bird poison. Then I seen what you were talking about. Thats crazy. But you might be on to something. If its cheaper we may have to buy that too. Called the Dr. today to get the new Ampyra (fampridine sr), Dr. doesn't know anything about it yet, waiting on the pharmacy rep to visit them before he writes any scripts. Then they go on to tell me that our insurance company probably wont pay for 6 months as they having a standing policy on any new drug to wait it out for 6 months. We have been waiting so long and now wait another 6 months. Never mind the clinical trials.

  7. #127
    Junior Member
    Join Date
    Mar 2010
    Location
    New Hampshire
    Posts
    3

    Acorda Press release for prescription availability

    New to this as a care giver for 6 mos SCi patient, my son.

    Acorda's press release dated March 1, 2010 is found at: http://phoenix.corporate-ir.net/phoe...6678&highlight=

    Would like to hear any more targeted information on improved bladder function in SCI with use of this drug.

    Thanks and best regards, Jim

    PS - Looking for more info from any users who have experienced improved bladder function (e.g. reduced spasticity)
    Last edited by BJames; 03-09-2010 at 01:06 PM. Reason: clarifying

  8. #128
    Senior Member trekker6's Avatar
    Join Date
    Mar 2011
    Location
    merritt island, florida
    Posts
    2,843
    I was going to start a new 4-ap experience thread but found this one, I just got a script for 4-ap from my doctor and am excited to see if it works for me, I'm on a slower ramp than Wise Young recommends, I'm impatient, but it's my physiatrists call.

    To start, I'm a 63 year old c-4 quadriplegic, incomplete, three and a half years post, I can walk, have limited use of hands, have sensation all over, not all good, suffer severe spasticity, although I can control my limbs, it feels like every muscle has an opposing muscle that fights it, does a muscle have several controlling nerves? I have bowel and bladder control although not great, suffer with constipation and spastic bladder. I walk but do so like frankenstein, have very little stamina and and am short of breath. It could have been a lot worse, but we always want more, I find I have the physical capabilities of a weak 90 year old man without fine motor control of my hands. This was not my plan for retirement, the first thing I was going to do was the Appalachian trail in its entirety, then go sailing to Europe and circumnavigate, I still have my sailboat, but haven't used it since my accident.
    Last edited by trekker6; 11-22-2014 at 02:28 PM.
    "Would you rather reduce deficits and interest rates by raising revenue from those who are not now paying their fair share, or would you rather accept larger budget deficits, higher interest rates, and higher unemployment? And I think I know your answer." Ronald Reagan"

  9. #129
    Great dedication trekker6! Please post about your experience!
    I am trying to get 4-ap but here in Canada since drug Fampridine (based on 4-ap and $ 600 per month) came to drugstores
    it is impossible to get generic compound 4-ap.
    I have called several compound drugstores in US but no luck.
    If anyone knows how to get it - I would be GRATEFUL!!!!
    p.s. I can get my Canadian Doctor prescribe Fampridine (as this slow release version of 4-ap is approved...)



    Quote Originally Posted by trekker6 View Post
    I was going to start a new 4-ap experience thread but found this one, I just got a script for 4-ap from my doctor and am excited to see if it works for me, I'm on a slower ramp than Wise Young recommends, I'm impatient, but it's my physiatrists call.

    To start, I'm a 63 year old c-4 quadriplegic, incomplete, three and a half years post, I can walk, have limited use of hands, have sensation all over, not all good, suffer severe spasticity, although I can control my limbs, it feels like every muscle has an opposing muscle that fights it, does a muscle have several controlling nerves? I have bowel and bladder control although not great, suffer with constipation and spastic bladder. I walk but do so like frankenstein, have very little stamina and and am short of breath. It could have been a lot worse, but we always want more, I find I have the physical capabilities of a weak 90 year old man without fine motor control of my hands. This was not my plan for retirement, the first thing I was going to do was the Appalachian trail in its entirety, then go sailing to Europe and circumnavigate, I still have my sailboat, but haven't used it since my accident.
    www.MiracleofWalk.com

    Miracles are not contrary to nature, but only contrary
    to what we know about nature
    Saint Augustine

  10. #130
    Senior Member trekker6's Avatar
    Join Date
    Mar 2011
    Location
    merritt island, florida
    Posts
    2,843
    I've heard some of the compounding pharmacies will mail to canada with a prescription, for a months supply I'm going to pay under 60 dollars, that's 120 10 mg pills. I've been quoted prices up to 120 for a months supply.

    Get a hold of Lynnifer, she gets ampyra I believe, she'll know what you can do.
    "Would you rather reduce deficits and interest rates by raising revenue from those who are not now paying their fair share, or would you rather accept larger budget deficits, higher interest rates, and higher unemployment? And I think I know your answer." Ronald Reagan"

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •